

available at [www.sciencedirect.com](http://www.sciencedirect.com)  
journal homepage: [www.europeanurology.com](http://www.europeanurology.com)



European Association of Urology



## Prostate Biopsy: The Transperineal Approach

Antonio Galfano<sup>a</sup>, Giacomo Novara<sup>a,b</sup>, Massimo Iafrate<sup>a</sup>, Marco Cosentino<sup>a</sup>, Stefano Cavalleri<sup>a</sup>, Walter Artibani<sup>a</sup>, Vincenzo Ficarra<sup>a,\*</sup>

<sup>a</sup> Department of Oncological and Surgical Sciences, Urology Clinic, University of Padua, Padua, Italy

<sup>b</sup> I.R.C.C.S. Istituto Oncologico Veneto, University of Padua, Padua, Italy

### Article info

#### Keywords:

Prostate biopsy  
Prostate cancer  
Transperineal  
Transrectal  
TRUS



[www.eu-acme.org/](http://www.eu-acme.org/)  
[europeanurology](http://europeanurology.com)

### Abstract

**Objective:** Review the literature concerning transperineal transrectal ultrasound (TRUS)-guided prostate biopsy (PBx), providing an update on the topic.

**Methods:** The literature review was performed using PubMed through a free text search strategy. The authors reviewed the abstracts of the retrieved records to select the relevant papers.

**Results:** The search retrieved 196 records; 68 were relevant to the issue. No high-level evidence recommends a particular kind of preparation/prophylaxis for transperineal PBx. It can be performed with a brachytherapy template under general or spinal anesthesia, or with a local periprostatic nerve block through a single-access fan technique. In the former case, up to 50 cores are obtained; in the latter, 12–26 cores. Prostate cancer detection rates range from 24% to 51%, with figures of 27–49% in patients undergoing their first PBx for a prostate-specific antigen level of 4–10 ng/ml. Such percentages are directly related to the number of cores obtained. In repeat biopsy and in prostates > 50 cc, the number of cores should be increased, paying particular attention in sampling the anterior zone. Among the studies comparing transrectal and transperineal PBx, only two demonstrated differences in detection rates in favor of the transperineal approach. Major complications are rare, with fever occurring in 0–5.2% and hospitalization in 0–1.4% of cases.

**Conclusion:** Transperineal TRUS-guided PBx is a safe procedure, with high detection rates and wide applications both in first and in repeat sampling. Although having a strong rationale, the transperineal approach has so far not resulted in higher detection rates than transrectal biopsies.

© 2007 European Association of Urology and European Board of Urology.  
Published by Elsevier B.V. All rights reserved.

\* Corresponding author. Department of Oncological and Surgical Sciences, Urology Clinic, University of Padua, Via Giustiniani, 2, 35100 Padova, Italy. Tel. +39 049 8212720; Fax: +39 049 8218757.

E-mail address: [vincenzo.ficarra@unipd.it](mailto:vincenzo.ficarra@unipd.it), [vincenzoficarra@hotmail.com](mailto:vincenzoficarra@hotmail.com) (V. Ficarra).

## 1. Introduction

From an historical viewpoint, the transperineal route has been the first one to be used to reach the prostate, both for diagnostic and therapeutic purposes [1]. For histologic diagnosis of prostate cancer, surgical perineal prostate biopsy (PBx) first and finger-guided perineal punch biopsy later on were the only possible approaches in the early 20th century [2].

The transrectal route has been used for finger-guided PBx since the mid-1950s [3], becoming the gold standard after Hodge et al demonstrated higher detection rates for sextant transrectal ultrasound (TRUS)-guided PBx than for sextant finger-guided analog sampling [4].

To date, because it seems to be more invasive and difficult, the TRUS-guided transperineal route is less used worldwide than the transrectal one, with figures ranging from 1.9% to 25% of the biopsies [5,6]. Nevertheless, supporters of such an approach report a lower risk for infective complications, a more selective sampling of the peripheral gland [7,8], an easier approach to the anterior zone of the prostate [9], and a higher detection rate [10] than transrectal PBx.

With this perspective, the aim of our study was to review the literature concerning transperineal TRUS-guided PBx and to provide up-to-date recommendations on the topic.

## 2. Methods

The review of the literature was performed using PubMed through a free text search strategy including the following entry terms: "transperineal" or "trans-perineal" or "perineal" and "prostate biopsy." The following limits were used to restrict the search: publication date after 1987, English, Title/Abstract. The authors reviewed the abstracts of the retrieved records to select the papers relevant to the topic of the study.

All the papers were ranked according to the grade of evidence as stated by Phillips and Sackett [11]. Meta-analyses of randomized clinical trials (RCTs) constitute the highest evidence (level 1a), followed by an adequately sampled, single RCT (level 1b); low-quality RCTs, prospective cohort studies, and high-quality case-control studies give level 2 evidence. A lower grade of evidence was provided by retrospective case-control studies or good-quality case series (level 3), whereas poor-quality case series, case reports, or expert opinion provide level 4 evidence [11].

## 3. Results

The search retrieved 196 records. Abstracts concerned with the issue of transperineal PBx numbered 68. The full texts of the 68 interesting articles

were reviewed. No level 1a evidence was retrieved and only two randomized trials (level 1b) were found [8,12]. Among those with level 2 evidence, most of the studies comparing different biopsy approaches or different core numbers used the same patients as internal controls [10,13-16]. Two further studies evaluated computer- or autopsy-based simulations of different approaches for PBx [7,17]. The remaining articles described non-controlled case series or case reports (level 3-4).

### 3.1. Preparation

No study specifically dealing with antibiotic prophylaxis, bowel preparation, or anticoagulant therapy suspension in transperineal PBx was retrieved.

Because the biopsy needle does not pass through the rectum, the transperineal approach should be considered a sterile procedure. For this reason, antibiotic prophylaxis should be recommended only for patients with a high risk of infection, such as diabetic or immunosuppressed patients, those with a poor general health status, cardiac prostheses, or cardiac valve pathologies, and those with an indwelling catheter or high postvoiding residual. In those patients, fluoroquinolones are indicated as first-choice antimicrobials. Alternatively, ampicillin,  $\beta$ -lactamase inhibitors, cephalosporins, or cotrimoxazole can be used as second-choice antibiotics. For patients with cardiac valve pathologies or prostheses, double antibiotic prophylaxis with ampicillin/vancomycin associated with aminoglycosides is indicated [18,19]. No univocal indication exists concerning the length of antibiotic prophylaxis in these patients. Similarly to what happens with the transrectal route, antibiotic usage should be prolonged for 3 d [20]. According to descriptive literature data, most of the centers performing transperineal PBx usually prescribe an antibiotic prophylaxis the day before the procedure; only some of them continue antibiotic usage for 2-3 d after the procedure [6,12,21]. In our clinical practice [13], we prefer to use antimicrobial prophylaxis in all patients scheduled for PBx. Our scheme includes a single-dose fluoroquinolone before the procedure. In our series, clinically significant urinary tract infections occurred in < 1% of cases. Only 3 patients (0.6%) of the 480 prospectively evaluated needed hospitalization for fever and urinary tract infections [13].

Roughly 80% of urologists will prescribe an enema as a preparation for transrectal PBx [22]. The reduction of the bacterial load on rectal mucosa may decrease procedure-related infections [23]. More recent data, from a Japanese PBx survey

including both transrectal and transperineal procedures (76% and 24%, respectively) report the use of a cleansing enema in only 44% of cases [6]. In transperineal biopsies, because the needle is not contaminated by fecal material, a preparation enema may be pointless. Nevertheless, currently it is preferable to perform an enema some hours before the procedure. In this way it is possible to reduce the discomfort due to the concomitant presence of the transrectal probe and fecal material in the rectum and to improve the quality of the ultrasound image [19].

As far as anticoagulant therapy is concerned, no specific study dealt with transperineal PBx. The few studies concerning transrectal PBx and suspension of anticoagulant therapy concluded there were no advantages in patients suspending aspirin ingestion before biopsy [24,25]. A recent meta-analysis confirmed such conclusions [26] and more recent data from a survey report 59% of United Kingdom urologists do not stop aspirin before PBx because the cerebrovascular risks of stopping aspirin outweigh the benefits on bleeding expected by aspirin discontinuation [27]. Similar conclusions have been drawn concerning with warfarin and other anti-coagulants [28].

### 3.2. Transperineal biopsy technique

We retrieved 28 articles from 16 groups describing a transperineal PBx (Table 1). Five groups performed the biopsy through the guide of a brachytherapy template device, with one skin puncture for each single core, whereas 11 used a fan technique, using a common access for all the cores. All authors

performed this kind of biopsy in the dorsal lithotomy position (only 1 used the extended lithotomy [33]), exposing the perineum and executing TRUS as a preliminary procedure.

#### 3.2.1. Anesthesia

Even though no specific study compared different kinds of anesthesia for transperineal PBx, all authors agree with the need to perform some kind of anesthesia.

Among the authors performing PBx with the fan technique, some groups preferred spinal anesthesia, whereas others performed the biopsy under local anesthesia with a periprostatic nerve block. Regional differences exist: for example, Japanese authors prefer the locoregional approach, whereas Italian ones routinely use local anesthesia (Table 1). Among the groups performing a transperineal PBx with the guide of a brachytherapy template, most of them use a general or spinal anesthesia. More specifically, the execution of multiple punctures on perineal skin and multiple perineal paths for the brachytherapy template makes it almost impossible to perform adequate local anesthesia; on the contrary, as the fan technique implies the execution of only one or two skin punctures following the same perineal path, local anesthesia is feasible with good results. For the execution of the periprostatic nerve block and for the following biopsies, some authors use a double access situated on the two sides of the midline above the anus at a 45° angle from midline at about 1.5 cm from the anus [21], whereas other authors prefer a single transperineal access on the midline 1.5 cm above the anus [12]. Though presenting a theoretically higher risk of

**Table 1 – Groups proposing an original transperineal prostate biopsy technique**

| Author              | Region | Anesthesia     | Template | Cores (range) | Set    |
|---------------------|--------|----------------|----------|---------------|--------|
| Saitoh 1997 [29]    | Japan  | Spinal         | No       | 12            | First  |
| Emiliozzi 2001 [21] | Italy  | Local          | No       | 12            | First  |
| Kojima 2001 [30]    | Japan  | Spinal         | No       | 12            | First  |
| Igel 2001 [31]      | USA    | General/spinal | Yes      | 17            | Repeat |
| Novella 2003 [12]   | Italy  | Local          | No       | 14            | First  |
| Kawakami 2004 [32]  | Japan  | Spinal         | No       | 14            | First  |
| Bott 2005 [33]      | UK     | General        | Yes      | 24 (12–36)    | Repeat |
| Pepe 2005 [34]      | Italy  | Local          | No       | 12–18         | First  |
| Satoh 2005 [9]      | Japan  | Spinal         | Yes      | 22            | Repeat |
| Watanabe 2005 [16]  | Japan  | Spinal         | No       | 6 TP + 6 TR   | First  |
| Yamamoto 2005 [35]  | Japan  | General        | No       | 12            | First  |
| Demura 2005 [36]    | Japan  | Spinal         | Yes      | 20 (9–38)     | Mixed  |
| Luciani 2006 [37]   | Italy  | Local          | No       | 12            | First  |
| Kawakami 2006 [38]  | Japan  | Spinal         | No       | 14 TP + 12 TR | First  |
| Takenaka 2006 [15]  | Japan  | Spinal         | No       | 12            | First  |
| Moran 2006 [39]     | USA    | General        | Yes      | 41            | Repeat |
| Merrick 2007 [40]   | USA    | General        | Yes      | 50            | Repeat |

TP = transperineal; TR = transrectal.

bulbar urethra and corpus spongiosus lesions, the median access reduces the risk of lesions to the bulbourethral arteries and perineal hematomas, thus improving the tolerability of the examination [12].

### 3.2.2. Fan technique

According to the conventional fan technique, biopsies are performed by repeatedly inserting the same biopsy needle through the anesthetized perineal path [21]. To minimize the invasiveness of the technique, a coaxial needle can be used with the aim of performing the several needle passages through the same path [12]. The coaxial needle makes the procedure easier and quicker, allowing the repeated introduction of the needle with low perineal trauma. The results of a prospective, randomized study comparing 51 patients undergoing conventional transperineal PBx and 51 patients undergoing transperineal PBx using the coaxial needle showed a reduction of pain during the biopsy and a better compliance for patients using the coaxial needle [12].

### 3.2.3. Template-guided stereotactic technique

With the aim of improving detection rates in patients with a previous negative biopsy or at high risk for prostate cancer, some authors proposed use

of the transperineal brachytherapy template device as a guide for the needle. This type of biopsy has been designed to perform saturation biopsy, being able to sample extensively the prostate with a higher tridimensional space control [31], but it has been used also for first-set biopsies [36,41]. The main disadvantage of this technique is the need for spinal or general anesthesia [42].

### 3.2.4. Number and location of cores

The optimal number and site of cores to be sampled in transperineal PBx is currently under debate [13]. Because the procedure is always preformed under anesthesia, the number of cores is usually higher than in the transrectal route, starting from 12 in the first set up to 50 in template saturation biopsies (Table 1).

Prostate cancer detection rates widely vary according to the population sampled (first or repeated biopsy), number of cores taken, prostate-specific antigen (PSA) value, and prostate volume (Table 2).

In patients undergoing their first PBx for a PSA between 4 and 10 ng/ml (Table 3), fan PBx yields a positive result in 27–45%; template PBx is rarely used in the first set, providing detection rates approximating 50%, whereas it is frequently used as a saturation sampling method in patients repeating PBx, providing a 22–43% rate of prostate cancer

**Table 2 – Features of the transperineal prostate biopsy published series**

| Author              | Patients | Cores (range) | PSA range      | Median PSA | Median postate volume | Negative DRE | First set | Template | Detection rate |
|---------------------|----------|---------------|----------------|------------|-----------------------|--------------|-----------|----------|----------------|
| Igel 2001 [31]      | 88       | 17            | NR             | 13.1       | NR                    | NR           | 0%        | Yes      | 43%            |
| Emiliozzi 2001 [21] | 141      | 12            | 4.1–5000       | 8          | NR                    | NR           | 100%      | No       | 51%            |
| Kojima 2001 [30]    | 541      | 12            | NA             | NR         | NR                    | 68.8%        | 100%      | No       | 24%            |
| Emiliozzi 2003 [10] | 107      | 6TR + 6TP     | 4–240          | 8.2        | NR                    | NR           | 100%      | No       | 40%            |
| Furuno 2004 [41]    | 113      | 18.2 (9–33)   | 4–10           | NR         | NR                    | 88.5%        | 23.9%     | Yes      | 42%            |
| Emiliozzi 2004 [8]  | 72       | 12            | 4–10           | NR         | NR                    | 71%          | 100%      | No       | 49%            |
| Kawakami 2004 [32]  | 289      | 14            | 2.5–40         | 10.7       | 47                    | 81.4%        | 100%      | No       | 36%            |
| Bott 2005 [33]      | 60       | 24 (18–36)    | 4.5–35.7       | 12.9       | 54                    | 93%          | 0%        | Yes      | 38%            |
| Demura 2005 [36]    | 371      | 20.1 (9–38)   | NR             | NR         | 42.5                  | 63.6%        | 84.1%     | Yes      | 49%            |
| Pinkstaff 2005 [43] | 210      | 21.212–41)    | NR             | 13.6       | NR                    | NR           | 0%        | Yes      | 37%            |
| Ficarra 2005 [13]   | 480      | 14            | 2.5–20         | 7.6        | 41.6                  | 67.3%        | 100%      | No       | 44%            |
| Pepe 2005 [34]      | 372      | 12–18         | NR             | NR         | NR                    | 76.1%        | NR        | No       | 42.7%          |
| Satoh 2005 [9]      | 128      | 12            | 2.4–170        | 10.3       | 43.9                  | 98.5%        | 0%        | Yes      | 22.7%          |
| Watanabe 2005 [16]  | 402      | 6TR + 6TP     | 0.6–460        | NR         | NR                    | 67.8%        | 100%      | No       | 48.5%          |
| Yamamoto 2005 [35]  | 300      | 12            | 2.5–20         | 7.25       | 28.3                  | 35.1%        | 100%      | No       | 36%            |
| Moran 2006 [39]     | 180      | 41            | 0.8–40.1       | 8.1        | 46.5                  | NR           | 0%        | Yes      | 38%            |
| Kawakami 2006 [38]  | 321      | 14TP + 12TR   | 0.9–38         | 6          | 36                    | 82%          | 100%      | No       | 34%            |
| Luciani 2006 [37]   | 122      | 12            | > 0            | 16.3       | 38                    | 100%         | 100%      | No       | 75%            |
| Rocco 2006 [44]     | 63       | 12            | 0.2–9.1        | 1.2        | NR                    | NR           | 100%      | No       | 17.2%          |
| Takenaka 2006 [15]  | 247      | 12            | 3.2–99         | 9.4        | 39.2                  | 75.3%        | 76.6%     | No       | 39.7%          |
| Merrick 2007 [40]   | 102      | 50            | NR             | 8.3        | 78.6                  | NR           | 1%        | Yes      | 42%            |
| Kawakami 2007 [14]  | 235      | 14TP + 12TR   | 5.8–2.2 (i.r.) | 8.3        | 41                    | 82%          | 0%        | No       | 37%            |

PSA = prostate-specific antigen; DRE = digital rectal examination; TP = transperineal; TR = transrectal; NR = not reported; NA = not available  
i.r. = interquartile range.

**Table 3 – Cancer detection rates in patients undergoing the first transperineal prostate biopsy for 4–10 ng/ml PSA**

| Author              | Patients | Cores (range) | Template | Detection rate |
|---------------------|----------|---------------|----------|----------------|
| Emiliezzi 2001 [21] | 97       | 12            | No       | 45%            |
| Kojima 2001 [30]    | 541      | 12            | No       | 40.8%          |
| Emiliezzi 2003 [10] | 70       | 6TP + 6TR     | No       | 30%            |
| Emiliezzi 2004 [8]  | 72       | 12            | No       | 49%            |
| Kawakami 2004 [32]  | 148      | 14            | No       | 27%            |
| Furuno 2004 [41]    | 86       | 18 (9–33)     | Yes      | 49%            |
| Ficarra 2005 [13]   | 389      | 14            | No       | 42.4%          |
| Watanabe 2005 [16]  | 180      | 14TP + 12TR   | No       | 33.9%          |
| Yamamoto 2005 [35]  | 184      | 12            | No       | 31%            |

PSA = prostate-specific antigen; TP = transperineal; TR = transrectal.

diagnoses. Such detection rates are usually higher than in transrectal saturation biopsies, reportedly between 13% and 41% [45]. Probably, this might be justified by the higher precision in sampling all prostatic zones and in particular the anterior part of the gland [41].

To date, six studies have compared schemes sampling a different core number, two using different patient samples [8,34] and four using internal controls [13–15,40]. Emiliezzi et al demonstrated an increasing detection rate with higher core numbers, particularly in patients with a PSA of 4–10 ng/ml (30% in 6-core transperineal biopsy vs. 49% in 12-core transperineal biopsy). Pepe et al confirmed these data comparing 12 versus 18 transperineal cores, with detection rates reaching 35% and 51%, respectively [34].

In the studies comparing different schemes through a recursive partitioning within the same patient population, Takenaka et al compared their complete scheme (12 cores) with the standard sextant, obtaining a 20% increase in diagnoses with the additional cores [15]. More detailed studies have been conducted by Ficarra et al in 2005 and by Merrick et al in 2007; both of them confirmed an increase in diagnoses proportional to the increase in core number, reaching 43.8% detection rates in a 14-core first biopsy series [13] and 42.1% in a 24-core repeat biopsy series [40]. These two studies report prostate volume as the strongest predictor for prostate cancer detection [13,40], highlighting the need to increase the number of cores in prostates > 50 cc [13].

Another variable to be taken into account for prostate cancer detection is the location of the cores. In studies coming from transrectal biopsy series, prostate cancer has been reported to be located in the peripheral zone in 85% of nonpalpable [46] and in 74% of palpable tumors [47].

On the other hand, transperineal PBx series demonstrate that up to 70% of prostate cancers are located in the anterior part of the prostate [32],

with a more frequent involvement of this area in nonpalpable cancers than in palpable ones [32,36] and in repeat biopsy than in the first set [9,41]. Moreover, the transitional zone is involved by cancer in up to 76% of patients with a positive result after a repeat biopsy with a transperineal template approach [31].

With this perspective, prostate sampling should include at least a minimum number of anterior cores in the first set, preferably in the far lateral peripheral zone (anterior horn). According to Ficarra et al, sampling this region with a single core per lobe provides an additional cancer diagnosis in 11% of cases [13].

According to these data, it seems reasonable to deduce that in the first transperineal biopsy setting a minimum of 12 cores should be taken, including the far lateral peripheral zone (anterior horn). Sampling of the transition zone might be omitted in these patients. On the other hand, repeat PBx should include a thorough sampling of the posterior and anterior zones, including transitional cores (Fig. 1). The brachytherapy template in repeat biopsy theoretically provides a more rational prostatic sampling, even though higher anesthetic support is necessary.

### 3.2.5. Comparing transperineal and transrectal PBx

Five studies have been identified comparing transrectal and transperineal PBx, all of them performing transperineal and transrectal PBx on the same patients (Table 4). The first one [7] was a simulation of transperineal (longitudinal) and transrectal (transverse) PBx conducted on radical prostatectomy surgical specimens. In this study, cancer had been initially diagnosed through transrectal biopsy. Nevertheless, 82.5% of the 40 analyzed cancers was redetected by sextant transperineal biopsy, whereas only 72.5% of cases was redetected by transrectal sextant biopsy. These experimental data were confirmed in clinical practice in 2003, when Emiliezzi et al studied 107 patients under-




**Fig. 1 – Number and location of cores in transperineal prostate biopsy.** 1–6 (black) sextant cores; 7–12 (yellow) lateral sextant cores; 13–14 (orange) transition zone cores. Not numbered (pink) cores: possible additional cores in the anterior zone of the prostate.

going 12 biopsies using a combination of the transrectal (6 cores in the peripheral zone) and transperineal (6 cores in the peripheral zone) approach. The authors reported higher detection

rates for the transperineal technique. In particular, the study showed an overall cancer detection rate of 40%, with 38% imputable to transperineal 6-core biopsy and 32% due to 6-core transrectal approach. In the subset of patients with a PSA of 4–10 ng/ml, the detection rates of the transperineal and transrectal biopsy were 27% and 20%, respectively [10]. A nearly identical study was performed by Watanabe et al, with different results. In their study, the authors reported an overall detection rate of 48%, significantly lower than the one produced by the six transrectal cores (40%) or by the one produced by the transperineal ones (41.2%). This difference could be due to the different prostatic sampling (6 peripheral transrectal cores versus 4 peripheral and 2 transitional transperineal cores) [16].

A different scenario was proposed by Kawakami et al, one using a systematic transrectal (12 cores) and transperineal (14 cores) prostatic sampling in patients undergoing their first [38,48] or repeated biopsy [14]. In both cases, the route of sampling

**Table 4 – Studies comparing transrectal versus transperineal prostate biopsy**

| Author              | Patients | Cores       | PSA range       | Set    | Detection rate (all) | Detection rate (TR) | Detection rate (TP) | p (TR vs. TP) | p (TP vs. all) |
|---------------------|----------|-------------|-----------------|--------|----------------------|---------------------|---------------------|---------------|----------------|
| Vis 2000 [7]        | 40       | 6TR + 6 TP  | NA              | NA     | NA                   | 72.5%               | 82.5%               | NR            | NR             |
| Emiliozzi 2003 [10] | 107      | 6TR + 6TP   | 4–240           | First  | 40%                  | 32%                 | 38%                 | 0.012         | >0.05          |
| Watanabe 2005 [16]  | 180      | 6TR + 6TP   | 4–10            | First  | 48.5%                | 40%                 | 41.3%               | >0.05         | 0.019          |
| Kawakami 2006 [38]  | 321      | 14TP + 12TR | 0.9–38          | First  | 34%                  | 21.1%               | NR                  | NR            | NR             |
| Kawakami 2007 [14]  | 235      | 14TP + 12TR | 5.8–12.2 (i.r.) | Repeat | 37%                  | 29.3%               | 30.2%               | >0.05         | >0.05          |

PSA = prostate-specific antigen; TP = transperineal; TR = transrectal; NA = not applicable; NR = not reported; i.r.: interquartile range.

**Table 5 – Major complications of transperineal prostate biopsy series**

| Author              | Patients | Cores        | Set    | Severe hematuria | AUR  | Fever | Hospitalization |
|---------------------|----------|--------------|--------|------------------|------|-------|-----------------|
| Emiliozzi 2001 [21] | 141      | 12           | First  | NR               | 0.7% | 0%    | 0%              |
| Kojima 2001 [30]    | 679      | 12           | First  | 2.6%             | 7.2% | 5.2%  | NR              |
| Igel 2001 [31]      | 88       | 17 T         | Repeat | 3.4%             | 2.2% | 1.1%  | 0%              |
| Emiliozzi 2003 [10] | 107      | 6TP + 6TR    | First  | NR               | 0%   | 0%    | 0%              |
| Novella 2003 [12]   | 102      | 14           | First  | NR               | 3%   | 1%    | 0%              |
| Emiliozzi 2004 [8]  | 107      | 12           | First  | NR               | 0%   | 0%    | 0%              |
| Kawakami 2004 [32]  | 289      | 14           | First  | 1%               | 0%   | 0%    | 1.4%            |
| Buskirk 2004 [49]   | 157      | 12           | First  | NR               | 11%  | NR    | NR              |
| Furuno 2004 [41]    | 113      | 18 T         | Mix    | NR               | 1%   | 0%    | 0%              |
| Ficarra 2005 [13]   | 480      | 14           | First  | 0.4%             | 0.6% | 0.6%  | 0.6%            |
| Pepe 2005 [34]      | 372      | 18           | NR     | NR               | 4.3% | 0.8%  | NR              |
| Watanabe 2005 [16]  | 402      | 6TR + 6TP    | First  | 0.5%             | 0.5% | 0.5%  | NR              |
| Bott 2005 [33]      | 60       | 24 T         | Repeat | 2%               | NR   | NR    | NR              |
| Demura 2005 [36]    | 371      | 20 T         | Repeat | 1.6%             | 1.6% | 0%    | 0               |
| Pinkstaff 2005 [43] | 210      | 21 T         | Repeat | NR               | 11%  | NR    | NR              |
| Satoh 2005 [9]      | 128      | 18 T         | Repeat | NR               | 3.2% | 0.8%  | 0.8%            |
| Kawakami 2006 [38]  | 321      | 12TR + 14TP  | First  | NR               | 0%   | 0.6%  | 0.6%            |
| Moran 2006 [39]     | 180      | 41 T         | Repeat | NR               | 10%  | NR    | NR              |
| Merrick 2007 [40]   | 102      | 50 T         | Repeat | 1%               | 38%  | NR    | NR              |
| Kawakami 2007 [14]  | 235      | 12TR + 14 TP | Repeat | 0.4%             | 0.4% | 0.8%  | 1.3%            |

AUR = acute urinary retention; TP = transperineal; TR = transrectal; T = template; NR = not reported; i.r. = interquartile range.

seems not to affect the ability to detect prostate cancer (88% vs. 88% of the cancers in the first biopsy set and 79% vs. 82% in repeat biopsy), whereas the combination of the two techniques allowed detection of a significantly higher number of cancers, with an overall cancer diagnosis of 34% in case of first biopsy and of 37% in case of repeat biopsy [14,48].

Unfortunately, no study specifically assessed the differences in time consumption and in costs for these two techniques. Nevertheless, because the only differences are in patient preparation and position and the materials to be used are similar, it can be supposed that no substantial differences exist between transrectal and transperineal PBx.

In conclusion, though having a strong rationale, the transperineal approach has not convincingly been demonstrated to provide detection rates higher than transrectal biopsy. High-quality, comparative studies must be performed to assess which kind of biopsy provides better results.

### 3.3. Complications

Most of the series reporting on transperineal PBx provide data concerning the complications related to the procedure. According to those data, transperineal biopsy is a safe procedure. Major complications, such as severe hematuria, acute urinary retention, fever, and other problems requiring hospitalization are rare (Table 5). Considering that in transperineal PBx the needle does not pass through the rectum, fever occurs in 0–1% of cases. Only one series reports fever occurring in 5.2% of cases [30].

Minor complications are more frequent but, because they rarely need treatments, they are seldom reported. In particular, self-limiting hematuria occurs in percentages ranging from 8.6% [34] to 52% [12], hemospermia happens in up to 79% of patients [8], and perineal discomfort or perineal hematoma has lower percentages (1–6%) [12,21]. Unfortunately, only a few authors reported the methods used to collect data concerning complications.

## 4. Conclusion

Transperineal TRUS-guided PBx is a safe procedure, with high detection rates and low morbidity.

The specific preparation for transperineal biopsy has not been studied through prospective controlled studies. Because the infectious risk of this procedure seems to be low, a single-dose fluoroquinolone prophylaxis has been advised in patients with a

standard risk for infection. The execution of a cleansing enema is recommended, and anticoagulant therapy should be stopped only if the hemorrhagic risk exceeds the thrombotic risk.

At least local anesthesia with periprostatic nerve block should be performed. Particularly in repeat PBx or when using the brachytherapy template, some groups propose using spinal or (more rarely) general anesthesia.

Because 6-core schemes provide insufficient detection rates, at least 12 cores are usually taken in the first prostatic sampling. Repeat biopsy, with or without a brachytherapy template, should include more cores, with particular attention to the anterior zone of the prostate.

High-quality, randomized, controlled studies must be performed to support the available evidence that the transperineal approach provides better results than the transrectal one both in terms of complications and results.

### Conflicts of interest

The authors have nothing to disclose.

### References

- [1] Wangenstein OH, Wangenstein SD. Lithotomy and lithotomists. In: The rise of surgery from empiric craft to scientific discipline. Minneapolis, MN: University of Minnesota Press; 1978. p. 71–80.
- [2] Barringer BS. Carcinoma of the prostate. Surg Gynecol Obstet 1922;34:168–76.
- [3] Daves JA, Tomskey GC, Cohen AE. Transrectal needle biopsy of the prostate. J Urol 1961;85:180–2.
- [4] Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989;142: 71–4.
- [5] Shandera KC, Thibault GP, Deshon Jr GE. Variability in patient preparation for prostate biopsy among American urologists. Urology 1998;52:644–6.
- [6] Noguchi M, Matsuoka K, Koga H, Kanetake H, Nakagawa M, Naito S. A questionnaire survey of patient preparation and techniques for prostate biopsy among urologists in the Kyushu and Okinawa regions of Japan. Int J Clin Oncol 2006;11:390–5.
- [7] Vis AN, Boerma MO, Ciatto S, Hoedemaeker RF, Schroder FH, van der Kwast TH. Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy. Urology 2000;56:617–21.
- [8] Emiliozzi P, Scarpone P, DePaula F, et al. The incidence of prostate cancer in men with prostate specific antigen greater than 4.0 ng/ml: a randomized study of 6 versus

- 12 core transperineal prostate biopsy. *J Urol* 2004;171:197-9.
- [9] Satoh T, Matsumoto K, Fujita T, et al. Cancer core distribution in patients diagnosed by extended transperineal prostate biopsy. *Urology* 2005;66:114-8.
- [10] Emiliozzi P, Corsetti A, Tassi B, Federico G, Martini M, Pansadoro V. Best approach for prostate cancer detection: a prospective study on transperineal versus transrectal six-core prostate biopsy. *Urology* 2003;61:961-6.
- [11] Phillips B, Ball C, Sackett D, et al. Levels of evidence and grades of recommendation. Oxford Centre for Evidence-Based Medicine. [http://www.cebm.net/levels\\_of\\_evidence.asp#levels](http://www.cebm.net/levels_of_evidence.asp#levels). Accessed May 2007.
- [12] Novella G, Ficarra V, Galfano A, et al. Pain assessment after original transperineal prostate biopsy using a coaxial needle. *Urology* 2003;62:689-92.
- [13] Ficarra V, Novella G, Novara G, et al. The potential impact of prostate volume in the planning of optimal number of cores in the systematic transperineal prostate biopsy. *Eur Urol* 2005;48:932-7.
- [14] Kawakami S, Okuno T, Yonese J, et al. Optimal sampling sites for repeat prostate biopsy: a recursive partitioning analysis of three-dimensional 26-core systematic biopsy. *Eur Urol* 2007;51:675-83.
- [15] Takenaka A, Hara R, Hyodo Y, et al. Transperineal extended biopsy improves the clinically significant prostate cancer detection rate: a comparative study of 6 and 12 biopsy cores. *Int J Urol* 2006;13:10-4.
- [16] Watanabe M, Hayashi T, Tsushima T, Irie S, Kaneshige T, Kumon H. Extensive biopsy using a combined transperineal and transrectal approach to improve prostate cancer detection. *Int J Urol* 2005;12:959-63.
- [17] Crawford ED, Wilson SS, Torkko KC, et al. Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy. *BJU Int* 2005;96:999-1004.
- [18] Naber KG, Bergman B, Bishop MC, et al. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). *Eur Urol* 2001;40:576-88.
- [19] Prayer-Galetti T, Ficarra V, Franceschini R, Liguori G, Martino P, Schiavina R, Gruppo Italiano Biopsia Prostatica. When to carry out prostate biopsy. *Arch Ital Urol Androl* 2005;77(3 suppl 1):3-16.
- [20] Griffith BC, Morey AF, Ali-Khan MM, Canby-Hagino E, Foley JP, Rozanski TA. Single dose levofloxacin prophylaxis for prostate biopsy in patients at low risk. *J Urol* 2002;168:1021-3.
- [21] Emiliozzi P, Longhi S, Scarpone P, Pansadoro A, DePaula F, Pansadoro V. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. *J Urol* 2001;166:845-50.
- [22] Davis M, Sofer M, Kim SS, Soloway MS. The procedure of transrectal ultrasound guided biopsy of the prostate: a survey of patient preparation and biopsy technique. *J Urol* 2002;167:566-70.
- [23] Jeon SS, Woo SH, Hyun JH, Choi HY, Chai SE. Bisacodyl rectal preparation can decrease infectious complications of transrectal ultrasound-guided prostate biopsy. *Urology* 2003;62:461-6.
- [24] Herget EJ, Saliken JC, Donnelly BJ, Gray RR, Wiseman D, Brunet G. Transrectal ultrasound-guided biopsy of the prostate: relation between ASA use and bleeding complications. *Can Assoc Radiol J* 1999;50:173-6.
- [25] Maan Z, Cutting CW, Patel U, et al. Morbidity of transrectal ultrasonography-guided prostate biopsies in patients after the continued use of low-dose aspirin. *BJU Int* 2003;91:798-800.
- [26] Burger W, Chemnitz JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention—cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation—review and meta-analysis. *J Intern Med* 2005;257:399-414.
- [27] Masood J, Hafeez A, Callear J, Barua JM. Aspirin use and transrectal ultrasonography-guided prostate biopsy: a national survey. *BJU Int* 2007;99:965-6.
- [28] Halliwell OT, Lane C, Dewbury KC. Transrectal ultrasound-guided biopsy of the prostate: should warfarin be stopped before the procedure? Incidence of bleeding in a further 50 patients. *Clin Radiol* 2006;61:1068-9.
- [29] Saitoh M, Watanabe M, Iida A, Watanabe H. Perineal systematic biopsy of the prostate guided by ultrasound. *J Med Ultrasound* 1997;5(Suppl):47-50.
- [30] Kojima M, Hayakawa T, Saito T, Mitsuya H, Hayase Y. Transperineal 12-core systematic biopsy in the detection of prostate cancer. *Int J Urol* 2001;8:301-7.
- [31] Igel TC, Knight MK, Young PR, et al. Systematic transperineal ultrasound guided template biopsy of the prostate in patients at high risk. *J Urol* 2001;165:1575-9.
- [32] Kawakami S, Kihara K, Fujii Y, Masuda H, Kobayashi T, Kageyama Y. Transrectal ultrasound-guided transperineal 14-core systematic biopsy detects apico-anterior cancer foci of T1c prostate cancer. *Int J Urol* 2004;11:613-8.
- [33] Bott SR, Henderson A, Halls JE, Montgomery BS, Laing R, Langley SE. Extensive transperineal template biopsies of prostate: modified technique and results. *Urology* 2006;68:1037-41.
- [34] Pepe P, Aragona F. Prostate needle biopsy: 12 vs. 18 cores—is it necessary? *Urol Int* 2005;74:19-22.
- [35] Yamamoto S, Kin U, Nakamura K, et al. Transperineal ultrasound-guided 12-core systematic biopsy of the prostate for patients with a prostate-specific antigen level of 2.5–20 ng/ml in Japan. *Int J Clin Oncol* 2005;10:117-21.
- [36] Demura T, Hioka T, Furuno T, et al. Differences in tumor core distribution between palpable and nonpalpable prostate tumors in patients diagnosed using extensive transperineal ultrasound-guided template prostate biopsy. *Cancer* 2005;103:1826-32.
- [37] Luciani LG, De Giorgi G, Valotto C, Zanin M, Bierti S, Zattoni F. Role of transperineal six-core prostate biopsy in patients with prostate-specific antigen level greater than 10 ng/mL and abnormal digital rectal examination findings. *Urology* 2006;67:555-8.
- [38] Kawakami S, Hyochi N, Yonese J, et al. Three-dimensional combination of transrectal and transperineal biopsies for

- efficient detection of stage T1c prostate cancer. *Int J Clin Oncol* 2006;11:127-32.
- [39] Moran BJ, Braccioforte MH, Conterato DJ. Re-biopsy of the prostate using a stereotactic transperineal technique. *J Urol* 2006;176:1376-81.
- [40] Merrick GS, Gutman S, Andreini H, et al. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. *Eur Urol* 2007;52:715-24.
- [41] Furuno T, Demura T, Kaneta T, et al. Difference of cancer core distribution between first and repeat biopsy: in patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy. *Prostate* 2004;58:76-81.
- [42] Rabbani F. Editorial comment on: prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. *Eur Urol* 2007;52:723-4.
- [43] Pinkstaff DM, Igel TC, Petrou SP, Broderick GA, Wehle MJ, Young PR. Systematic transperineal ultrasound-guided template biopsy of the prostate: three-year experience. *Urology* 2005;65:735-9.
- [44] Rocco B, de Cobelli O, Leon ME, et al. Sensitivity and detection rate of a 12-core trans-perineal prostate biopsy: preliminary report. *Eur Urol* 2006;49:827-33.
- [45] Walz J, Graefen M, Chun FK-H, et al. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. *Eur Urol* 2006;50:498-505.
- [46] Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. *JAMA* 1994;271:368-74.
- [47] Chen ME, Johnston DA, Tang K, Babaian RJ, Troncoso P. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. *Cancer* 2000;89:1800-9.
- [48] Numao N, Kawakami S, Yokoyama M, et al. Improved accuracy in predicting the presence of Gleason pattern 4/5 prostate cancer by three-dimensional 26-core systematic biopsy. *Eur Urol*. In press. doi:10.1016/j.eururo.2007.01.025.
- [49] Buskirk SJ, Pinkstaff DM, Petrou SP, et al. Acute urinary retention after transperineal template-guided prostate biopsy. *Int J Radiat Oncol Biol Phys* 2004;59:1360-6.

### CME questions

Please visit [www.eu-acme.org/europeanurology](http://www.eu-acme.org/europeanurology) to answer these CME questions on-line. The CME credits will then be attributed automatically.

1. Transperineal prostate biopsy:
  - A. Has to be performed without the guide of transrectal ultrasound (TRUS).
  - B. Cannot be performed without general anesthesia.
  - C. Has to be performed in selected centers only.
  - D. Has to be performed with some kind of anesthesia.
2. In transperineal prostate biopsy, the template technique:
  - A. Requires multiple skin accesses and paths to take the cores.
  - B. Requires one or two skin accesses for all the cores.
  - C. Is the technique of implanting the seeds for brachytherapy at the same moment of prostate biopsy.
  - D. Has to be performed with three-dimensional ultrasound equipment.
3. A good-quality first-set transperineal prostate biopsy:
  - A. Should include at least six cores.
  - B. Should sample the anterior far lateral aspects of the prostate (anterior horn).
  - C. Should include at least four cores from the transition zone.
  - D. The transition zone should be sampled only for prostate-specific antigen levels > 10 ng/ml.
4. Comparing transperineal versus transrectal prostate biopsy:
  - A. There is a theoretical minor risk for infection in transperineal biopsy.
  - B. Detection rates are higher in transrectal procedures than in transperineal ones.
  - C. Transrectal biopsy requires a more difficult preparation.
  - D. Complication rates are higher in transperineal biopsy.
5. To improve detection rates, it is advisable:
  - A. To increase the number of cores proportionally to prostate-specific antigen levels.
  - B. To decrease the number of cores proportionally to the transition zone volume.
  - C. To increase the number of cores proportionally to prostate volume.
  - D. To decrease the number of cores in patients undergoing repeat biopsy.
6. In transperineal prostate biopsy, the cleansing enema:
  - A. Has the aim to reduce the bacterial load of the rectal mucosa.
  - B. Might improve TRUS images and reduce the discomfort during the procedure.
  - C. Is contraindicated.
  - D. Is rarely performed.